Objective. To evaluate the diagnostic value of gastrin-17 (G-17) and pepsinogen (PG) in gastric cancer (GC) screening in China, especially eastern China, and to determine the best diagnostic combination and threshold (cutoff values) to screen out patients who need gastroscopy. Methods. The serum concentrations of G-17 and pepsinogen I and II (PGI and PGII) in 834 patients were analyzed, and the PGI/PGII ratio (PGR) was calculated. According to pathological results, patients can be divided into chronic nonatrophic gastritis (NAG)/chronic atrophic gastritis (CAG)/intraepithelial neoplasia (IN)/GC groups. The differences in G-17, PG, and PGR in each group were analyzed, and their values in GC diagnosis were evaluated separately and in combination. Results. There were differences in serum G-17, PGII, and PGR among the four groups (NAG/CAG/IN/GC) ( ). In total, 54 GC cases were diagnosed, of which 50% were early GC. There was no significant difference in the PGI levels among the four groups ( ). NAG and CAG composed the chronic gastritis (CG) group. The G-17 and PGII levels in the IN and GC groups were higher than those in the CG group (both ), while the PGR levels were lower ( ). When distinguishing NAG from CAG, the best cutoff value for G-17 was 9.25 pmol/L, PGII was 7.06 μg/L, and PGR was 12.07. When distinguishing CG from IN, the best cutoff value for G-17 was 3.86 pmol/L, PGII was 11.92 μg/L, and PGR was 8.26. When distinguishing CG from GC, the best cutoff value for G-17 was 3.89 pmol/L, PGII was 9.16 μg/L, and PGR was 14.14. The sensitivity, specificity, accuracy, and positive and negative predictive values of G-17/PGII/PGR for GC diagnosis were 83.3%/70.4%/79.6%, 51.8%/56.3%/47.8%, 53.8%/57.2%/49.9%, 10.7%/10.9%/9.6%, and 97.8%/96.5%/97.1%, respectively. The sensitivity, specificity, accuracy, and positive predictive and negative predictive values of PGII/G-17 vs. PGR/G-17 vs. PGR/PGII in the diagnosis of GC were 63.0% vs. 70.4% vs. 64.8%, 70.5% vs. 70.1% vs. 60.4%, 70.0% vs. 70.1% vs. 60.7%, 12.9% vs. 14.0% vs. 10.2%, and 96.5% vs. 97.2% vs. 96.1%, respectively. Conclusion. The PGII and G-17 levels in patients with gastric IN and GC were significantly increased, while the serum PGR level was significantly decreased. Serological detection is effective for screening GC. The combination of different markers can improve the diagnostic efficiency. The highest diagnostic accuracy was G-17 combined with PGR, and the best cutoff values were and .
BACKGROUND: Large and impacted common bile duct stones (CBDSs) cannot be removed by conventional endoscopic retrograde cholangiopancreatography (ERCP), and extracorporeal shock wave lithotripsy (ESWL) or cholangioscopy-guided lithotripsy is recommended as a second-line treatment. The aim of this study is to compare safety and efficacy of ESWL for difficult CBDS. METHODS: Patients at our hospital diagnosed with complex large CBDS between January 2021 and June 2022 were randomly assigned to the ESWL group or the cholangioscopy group for lithotripsy. Our results include clinical and technical success, the mean number of ERCP sessions, and any complications from the procedure. RESULTS: A total of 84 patients were included assigned to two groups (the ESWL group [42 patients] and the cholangioscopy group [42 patients]). Technical success was 92.85% for the ESWL group and 100% for the cholangioscopy group (p = 0.19), whereas clinical success was 69% and 88%, respectively (p = 0.01). The ESWL group had 2.32 ± 0.98 ERCPs, and the cholangioscopy group had 1.13 ± 0.36 (p < 0.001). The mean lithotripsy sessions were 2.3 ± 0.63 for ESWL and 1.13 ± 0.36 for cholangioscopy (p < 0.001). Both groups had similar adverse events, except for cutaneous petechiae. CONCLUSION: Compared with ESWL, cholangioscopy-guided lithotripsy is a safe and effective treatment for large and complex CBDSs. LEVEL OF EVIDENCE: Therapeutic/Care Management; Level II.